Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...
The median follow-up of 37 months showed that PSMAiSRT improved FFS and eugonadal FFS, with significant improvements in the ...
The FDA has granted fast track designation to the investigational therapeutic agent WTX-124 for the potential treatment of ...
Patients in the no LND arm had shorter surgery duration, less blood loss, and reduced postoperative hospital stay compared to ...
A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options. Stephanie Lee, MD, MPH, professor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback